Salicyladehyde

Salicyladehyde

SCHEMBL901265

O=Cc1ccccc1O.O=Cc1ccccc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 1.00
TRIM33 Q9UPN9 1/20 1.00
ERN1 O75460 5/20 0.65
LMNA P02545 2/20 0.63
MEN1 O00255 1/20 0.63
THRB P10828 1/20 0.63
BLM P54132 1/20 0.63
KMT2A Q03164 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
CDK4 P11802 1/20 0.60
CCND1 P24385 1/20 0.60
NFKB1 P19838 2/20 0.54
JUN P05412 1/20 0.54
NFE2L2 Q16236 1/20 0.54
CA2 P00918 4/20 0.54
CA1 P00915 2/20 0.54
CA4 P22748 1/20 0.52
MAPT P10636 1/20 0.50
TRPA1 O75762 1/20 0.50
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Salicyladehyde SCHEMBL29386538 1.00
Salicyladehyde SCHEMBL15395 1.00
Salicyladehyde SCHEMBL4456334 0.97 TRIM24 (0.95) TRIM24TRIM33ERN1LMNAMEN1
Salicyladehyde SCHEMBL6151947 0.97 TRIM24 (0.95) TRIM24TRIM33ERN1LMNAMEN1
Salicyladehyde SCHEMBL6851494 0.97 TRIM24 (0.95) TRIM24TRIM33ERN1LMNAMEN1
Salicyladehyde SCHEMBL23389487 0.97 TRIM24 (0.95) TRIM24TRIM33ERN1LMNAMEN1
Salicyladehyde SCHEMBL5842615 0.97 TRIM24 (0.95) TRIM24TRIM33ERN1LMNAMEN1
Salicyladehyde SCHEMBL5121332 0.97 TRIM24 (0.95) TRIM24TRIM33ERN1LMNAMEN1
Salicyladehyde SCHEMBL1176891 0.97 TRIM24 (0.95) TRIM24TRIM33ERN1LMNAMEN1
Salicyladehyde SCHEMBL23628380 0.97 TRIM24 (0.95) TRIM24TRIM33ERN1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112585152-A Electrically readable read-only memory based on nucleic acids 加利福尼亚大学董事会 2021-03-30 CN disclosed
CN-103408458-B Bridged dialdehyde beta-amino alcohol acetal tetradentate two-chiral-center Schiff base compounds with, synthesis thereof and applications thereof UNIV ZHEJIANG TECHNOLOGY 2015-04-22 CN disclosed
EP-2788496-A1 METHOD OF DIAGNOSING PNEUMONIA BY DETECTING A VOLATILE ORGANIC COMPOUND Meon Medical Solutions GmbH & Co. KG (AT) 2014-10-15 EP disclosed
CN-103408458-A Bridged dialdehyde beta-amino alcohol acetal tetradentate two-chiral-center Schiff base compounds with, synthesis thereof and applications thereof UNIV ZHEJIANG TECHNOLOGY 2013-11-27 CN disclosed
EP-2621462-A1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR The Procter and Gamble Company (US) 2013-08-07 EP disclosed
WO-2013083518-A1 METHOD OF DIAGNOSING PNEUMONIA BY DETECTING A VOLATILE ORGANIC COMPOUND MEON MEDICAL SOLUTIONS GMBH & COKG (AT) 2013-06-13 WO disclosed
WO-2012044728-A1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR THE PROCTER & GAMBLE COMPANY (US) 2012-04-05 WO disclosed
US-7109211-B2 Substituted benzopyran derivatives for the treatment of inflammation PHARMACIA CORPORATION (OF PFIZER, INC.) (US) 2006-09-19 US disclosed
US-20050049252-A1 Substituted benzopyran derivatives for the treatment of inflammation G.D. SEARLE & CO. (US) 2005-03-03 US disclosed
US-6417195-B1 LIBRARIES AND COMBINATORIAL CHEMISTRY LION BIOSCIENCE AG (DE) 2002-07-09 US disclosed
US-5874443-A BIOSYNTHESIS TREGA BIOSCIENCES, INC. (US) 1999-02-23 US disclosed
US-4087402-A USED FOR TREATMENT OF INORGANIC FILLERS KENRICH PETROCHEMICALS, INC. (US) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049252-A1 Substituted benzopyran derivatives for the treatment of inflammation PTGES2, PTGS2, PTGER2 TRIM24 3726/4885TRIM33 3978/4885ERN1 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.